GlassScriptPhysician profile
Sonya Rane Saini
NPI 1073816096
$6,020.56
in general payments reported to CMS, 2019-2025
21 companies · $644 in 2025
The $644 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,178 · 2022: $1,832 · 2023: $1,631 · 2024: $736 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,066.37 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $826.88 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $781.62 | 2021-2025 | Fasenra, Tezspire, Farxiga |
| Optinose US, INC. | $600.27 | 2021-2024 | |
| Genzyme Corporation | $360.44 | 2021-2025 | |
| Amgen INC. | $351.16 | 2021-2023 | Tezspire |
| Genentech USA, INC. | $335.37 | 2021-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $197.79 | 2021-2023 | Cuvitru |
| Teva Pharmaceuticals USA, INC. | $196.65 | 2021-2022 | |
| Incyte Corporation | $186.01 | 2022-2023 | Opzelura |
| Pfizer INC. | $179.46 | 2021-2023 | |
| Csl Behring | $171.43 | 2021-2025 | Haegarda |
| Kaleo, INC. | $157.07 | 2021-2024 | Auvi-Q |
| Actelion Pharmaceuticals US, INC. | $136.95 | 2025 | Opsumit, Uptravi |
| Pharming Healthcare, INC. | $115.72 | 2022-2025 | Ruconest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $102.83 | 2021-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $90.81 | 2021-2024 | |
| Abbvie INC. | $90.38 | 2022-2023 | |
| Gc Biopharma USA, INC. | $34.11 | 2025 | Alyglo |
| Blueprint Medicines Corporation | $24.07 | 2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $15.17 | 2024 | Winrevair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.